To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Healthy Volunteers
Interventions
DRUG

Midazolam

Volunteers will receive a single dose of Midazolam 7.5 mg on Day 1

DRUG

AZD1722

Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14

DRUG

AZD1722 and Midazolam

On Day 15 volunteers will receive AZD1722 15 mg and Midazolam 7.5 mg at the same time in the morning. In the evening on Day 15 AZD1722 15 mg will be administered alone.

Trial Locations (1)

Unknown

Research Site, Overland Park

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ardelyx

INDUSTRY

NCT02140268 - To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers | Biotech Hunter | Biotech Hunter